Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

How safe is stem cell therapy for cerebral palsy?

Clinical studies of stem cell therapy in cerebral palsy (CP) have shown a generally reassuring short-term safety profile. In a meta-analysis of randomized trials, serious adverse events were rare and occurred at similar rates in children who received cells and in those who received standard care.

Free Consultation
Brain location on a neutral human figure

The most common side effects of intravenous (IV) mesenchymal stromal cell (MSC) infusions are temporary, such as low-grade fever, irritability, headache or tiredness. That said, safety in CP depends heavily on the individual: seizure control, breathing and swallowing, nutrition, the need for sedation, and the route of administration all matter. At Stem Cell Mexico, every case is reviewed by a specialist before acceptance, and treatment is declined when the risks outweigh the expected benefits.

Parents and caregivers deserve a clear, honest answer to this question. This guide explains what research shows, which factors increase or reduce risk, and how families can make a safe, informed decision.

What research shows about safety

Meta-analysis of randomized trials

A 2019 systematic review and meta-analysis in the World Journal of Stem Cells (Eggenberger and colleagues) analyzed randomized controlled trials of stem cell therapy in CP, pooling data from 282 patients in the meta-analysis. Serious adverse events were rare and equally distributed between the stem cell and control groups, supporting short-term safety.

Cord blood in young children

A randomized, placebo-controlled trial at Duke University, published in Stem Cells Translational Medicine in 2017 (Sun and colleagues), gave IV infusions of the children's own banked umbilical cord blood to 63 young children with CP. The infusions were well tolerated, and the study provided important data on dosing in children.

Umbilical cord MSCs more broadly

A 2026 systematic review in Stem Cells Translational Medicine (Hum and colleagues) analyzed 42 randomized trials with 2,280 patients receiving intravascular umbilical cord MSCs for a variety of conditions. It found an increased risk of temporary fever but no signals of harm for infection, thrombosis, malignancy, abnormal tissue formation or death, while recommending continued long-term monitoring.

What this means

Across studies, the short-term safety of cell therapy in CP and of umbilical cord MSCs in general appears favorable. Because CP often involves complex medical needs, careful individual screening is essential.

Understanding fever and irritability after an infusion

Temporary fever is the most consistently reported side effect of intravenous MSCs. In children, it may appear as a warm forehead, flushed cheeks, fussiness, poor appetite or extra sleepiness within hours of the infusion, usually resolving within one to two days. It is thought to reflect a short immune response to the cells rather than an infection. Nurses monitor temperature during observation, and paracetamol (acetaminophen) is generally used if needed. For children with epilepsy, fever can lower the seizure threshold, so temperature is watched closely and anti-seizure medications are never skipped. Any high, persistent or worsening fever should be reported promptly.

Safety by route of administration

  • Intravenous infusion: the most common route for CP protocols. It avoids surgery and is similar to receiving an IV medication. Temporary fever, irritability or fatigue are the most common effects.
  • Intrathecal (into the spinal fluid through a lumbar puncture): used in some studies. It can cause headache, back pain and, rarely, infection, and may require sedation in children.
  • Other routes, such as intra-arterial or direct brain injection, carry higher risks and are limited to research settings.

The route chosen for your child, and its specific risks, should be explained before any treatment.

CP-specific factors that affect safety

Seizures

Many children and adults with CP have epilepsy. Seizures should be well controlled before treatment, and anti-seizure medications must be continued on schedule during travel and treatment.

Breathing and swallowing

Children with more severe CP may have swallowing difficulties (dysphagia), a risk of aspiration or chronic respiratory problems. These affect the safety of sedation, feeding during the stay and positioning.

Nutrition and weight

Doses are calculated per kilogram of body weight, and nutritional status influences recovery. Feeding tubes and special diets are planned in advance.

Sedation

Some procedures may require sedation, especially in young children or those who cannot stay still. Sedation is managed by trained personnel with monitoring of breathing and oxygen levels, and its risks are reviewed with families beforehand.

Musculoskeletal and skin care

Hip problems, contractures and pressure areas require attention during transfers and positioning.

Infections and recent illness

Treatment is postponed if the child has an active infection, a recent respiratory illness or uncontrolled medical problems.

Adults with cerebral palsy

Cerebral palsy is often discussed as a childhood condition, but it is lifelong, and many adults with CP seek regenerative treatment for pain, stiffness, fatigue or joint problems that develop over time. Safety considerations in adults include age-related conditions such as high blood pressure, osteoporosis, early osteoarthritis and reduced mobility, as well as the medications used to manage spasticity and pain. In some adults, the most realistic goal may be relief of joint or musculoskeletal pain rather than changes in motor function, and a targeted joint treatment may be safer and more appropriate than a systemic protocol. The evaluation should reflect the adult's own priorities and medical history.

How we reduce risk

  • Specialist review of medical records, brain imaging, seizure history, medications and therapy reports before acceptance.
  • Pre-treatment testing appropriate for age and health.
  • Quality-controlled cells with donor screening, infectious disease testing, and laboratory quality testing before release.
  • Weight-based dosing and appropriate infusion speed with monitoring of vital signs.
  • Observation with nursing supervision after treatment.
  • Family involvement: caregivers are informed and involved in planning feeding, medication and comfort routines.
  • Clear instructions for recovery and follow-up.
  • Caution with combined procedures: we avoid scheduling other invasive procedures, such as orthopedic surgery or botulinum toxin injections, too close to the cell treatment unless the medical team confirms it is safe, so that any reaction can be clearly attributed and managed.

Preparing your child for the visit

Children cope better with medical visits when they know what to expect. Depending on age and understanding, explain the trip in simple terms, bring familiar comfort items such as a favorite blanket, toy or tablet, and keep routines for sleep, meals and medications as close to normal as possible. Pack enough of all medications in their original containers, along with a written schedule, feeding supplies and any equipment such as braces, a wheelchair or a stroller. Share with the team how your child communicates discomfort, what calms them and any sensory sensitivities, so staff can adapt the environment. Planning rest days before and after travel helps reduce fatigue and makes it easier to tell whether any changes after treatment are related to the therapy or simply to the trip.

Safety is not the same as effectiveness

A treatment can be safe and still not produce the improvement a family hopes for. The same meta-analysis found statistically significant improvements in motor function. Families should weigh both safety and realistic expectations. The U.S. Centers for Disease Control and Prevention (CDC) emphasizes that early, individualized therapies and medical care remain the foundation of CP management. Regenerative treatment, if chosen, should complement physical, occupational and speech therapy, not replace them.

Regulatory context

No stem cell product is approved by the FDA for cerebral palsy. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS. Ask any provider for documentation of the cell product and facility.

Who may be a safe candidate

  • Confirmed diagnosis of CP with stable general health.
  • Seizures controlled, if present.
  • No active infection or recent serious respiratory illness.
  • Breathing, swallowing and nutritional needs assessed and manageable.
  • Families with clear, measurable goals and continued access to therapy.

Signs to report after treatment

Contact the medical team or seek urgent care for a seizure, high or persistent fever, breathing difficulty, unusual drowsiness, refusal to feed, vomiting, rash or signs of infection at any injection site.

Questions families should ask

  • What route and dose do you recommend, and what are the specific risks for my child?
  • Will sedation be needed, and how will breathing be monitored?
  • How will seizures, feeding and medications be managed during the stay?
  • What documentation will we receive about the cells?
  • In what situations would you advise against treatment?

What our patients usually receive

Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:

  • Wharton's jelly MSCs by IV infusion, with the number of cells adjusted to body weight and confirmed after the doctor reviews the medical reports.
  • One night at our facilities, sometimes two, with nursing and medical monitoring and a parent or caregiver present.
  • Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
  • Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.

Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.

Bottom line

Stem cell therapy for cerebral palsy has shown a reassuring short-term safety profile in clinical studies, with mostly mild and temporary side effects, while long-term data continue to be collected. Safety depends on careful screening of seizures, breathing, swallowing, nutrition and sedation needs, along with quality-controlled cells and monitoring. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your child's or your own condition, goals and medical history.

References

  1. Eggenberger S et al. Stem cell treatment and cerebral palsy: systemic review and meta-analysis. World Journal of Stem Cells, 2019 (opens in a new tab)
  2. Sun JM et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Translational Medicine, 2017 (opens in a new tab)
  3. Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
  4. U.S. Centers for Disease Control and Prevention (CDC): Treatment and intervention for cerebral palsy (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation